|
Intestinal metaplasia
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Barrett's metaplasia was also associated with a specific MUC gene expression pattern, since the gastric apomucin mRNAs, MUC5AC and MUC6, were expressed in gastric metaplasia, and the intestinal apomucin mRNAs, MUC3, MUC4 and mostly MUC2, in intestinal metaplasia.
|
11093805 |
2000 |
|
Intestinal metaplasia
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Intestinal metaplasia is characterized by an intestinal-type pattern with MUC2 and MUC3 mRNA expression.
|
11101634 |
2000 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Comparable MUC1, MUC2, and MUC3 mRNA levels were present in adenomas and normal colon, whereas mucin mRNA levels were decreased in adenocarcinomas.
|
8859775 |
1996 |
|
Intestinal metaplasia
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, high levels of MUC2 and MUC3 mucin mRNA and immunoreactive protein were found in specimens with intestinal metaplasia.
|
7780985 |
1995 |
|
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both immunocytochemistry and in situ hybridization were used to identify cell types expressing the MUC2 and MUC3 mucins in the human small intestine, colon, and colon carcinoma.
|
8020672 |
1994 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Compared with corresponding normal tissue, MUC1 mRNA levels were increased in breast cancer and well-differentiated lung cancers, and MUC3 mRNA was increased in gastric adenocarcinomas.
|
7678777 |
1993 |
|
Colon Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MUC2 or MUC3 mRNA levels were increased in colloid colon cancer compared with normal colon, however in well- and moderately well-differentiated colon cancers MUC1, 2 and 3 mRNA levels were decreased.
|
7678777 |
1993 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in >20% of the carcinomas.
|
29575536 |
2018 |
|
Hyperplastic Polyp
|
0.020 |
Biomarker
|
disease |
BEFREE |
Improved diagnostic potential was revealed by multivariate logistic regression analysis where combinatorial panel of MUC5AC/MUC17 discriminated SSA/P from HP (SN/SP=85/82%).
|
27705923 |
2017 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Marked increased expression of MUC17, the cell junction protein genes VSIG1 and GJB5, and the antiapoptotic gene REG4 were found in SSA/Ps, relative to controls and adenomas, were verified by qPCR analysis of additional SSA/Ps (n = 21) and adenomas (n = 10).
|
24533081 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the kidney, MUC3 is expressed in normal convoluted tubules and in renal clear cell carcinoma.
|
14550470 |
2003 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest the implication of MUC3 in renal carcinogenesis.
|
14550470 |
2003 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
MUC1, MUC3 and MUC6 were expressed both in normal kidney and in renal carcinomas.
|
12010365 |
2002 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In renal carcinoma, we showed a heterogeneous expression of MUC1 and MUC3 with an over-expression of MUC3 in renal clear cell carcinoma.
|
12010365 |
2002 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The over-expression of MUC3 in renal cell carcinomas favours its implication in renal tumorigenesis.
|
12010365 |
2002 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Goblet cells expressing the MUC2 gene and columnar cells expressing the MUC3 gene were consistent with an intestinal phenotype, which was observed in 15 tumours (71%) including nine adenomas and six borderline tumours.
|
11241413 |
2001 |
|
Ulcerative Colitis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We reported a possible association of rare variable number of tandem repeat (VNTR) alleles of the "MUC3" gene with a susceptibility to UC.
|
11289722 |
2001 |
|
Ulcerative Colitis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This result suggests that rare alleles of the MUC3 gene may confer genetic predisposition to UC.
|
9931338 |
1999 |
|
Hyperplastic Polyp
|
0.020 |
Biomarker
|
disease |
BEFREE |
Expression of MUC1, MUC2, and MUC3 core tandem repeat proteins was examined in specimens of normal mucosa (n = 20), hyperplastic polyps (n = 10), adenomatous polyps (n = 89), and invasive cancer (n = 19).
|
8859775 |
1996 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Therefore, 13 novel loci (MOB3C‑TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, OR52E4, TCHP‑GIT2, CCDC63, 12q24.1, OAS3, PLCB2‑VPS33B, ZNF77, COL6A5, NFKBIL1‑NCR3, MUC17) were identified that confer susceptibility to early‑onset MI, hypertension, or CKD.
|
30226566 |
2018 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, 13 novel loci (MOB3C‑TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, OR52E4, TCHP‑GIT2, CCDC63, 12q24.1, OAS3, PLCB2‑VPS33B, ZNF77, COL6A5, NFKBIL1‑NCR3, MUC17) were identified that confer susceptibility to early‑onset MI, hypertension, or CKD.
|
30226566 |
2018 |